Pediatr. praxi. 2024;25(1):9-11 | DOI: 10.36290/ped.2024.001

Obesity in childhood and adolescence

MUDr. Petra Paterová, doc. MUDr. Renata Pomahačová, Ph.D., prof. MUDr. Josef Sýkora, Ph.D.
Dětská klinika FN a LF UK Plzeň

In the overview article, we will deal with the diagnosis of childhood overweight and obesity, the differential diagnosis of childhood obesity, and we will focus on new findings in the regulation of eating behavior. We will summarize the complications of this metabolic disease and mention the options for treating childhood obesity.

Keywords: obezita, jídelní chování, endokrinopatie, leptin, liraglutid.

Accepted: February 12, 2024; Published: February 19, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Paterová P, Pomahačová R, Sýkora J. Obesity in childhood and adolescence. Pediatr. praxi. 2024;25(1):9-11. doi: 10.36290/ped.2024.001.
Download citation

References

  1. Dětská obezita v ČR, Available from: https://szu.cz/wp-content/uploads/2023/02/obezita_web_2023.pdf.
  2. Lebl J, et kol. Dětská endokrinologie a diabetologie. Galén, 2016: 616 s.
  3. Pomahačová R, Paterová P, Nykodýmová E, et al. Endokrinní příčiny obezity v dětství a adolescenci. Ces-slov Pediat. 2022; 77(Suppl 3):S24-29. Go to original source...
  4. Lebl J, Malíková Křenek J, Hainerová Aldhoon I. Regulace energetické rovnováhy a jídelního chování. Ces-slov Pediat. 2023;78(1):48-53. Go to original source...
  5. Dlouhá D, Hubáček JA. Gen pro FTO a jeho role v genetické determinaci obezity. Vnitr Lek. 2012;58(3):208-215.
  6. Dubern B. Leptin Deficiency. 2015. Dostupné z: https://ebook.ecog-obesity.eu.
  7. Dubern B. MC4R and MC3R mutations. 2015. Available from: https://ebook.ecog-obesity.eu.
  8. Malíková Křenek J, Hainerová Aldhoon I, Lebl J. Současné možnosti farmakoterapie dětské obezity. Ces-slov Pediat. 2023;78(2):122-126. Go to original source...
  9. Malíková Křenek J, Lebl J. Analoga GLP-1 v léčbě obezity u adolescentů. První praktické zkušenosti s podáváním liraglutidu. Ces-slov Pediat. 2023;78(3):176-181. Go to original source...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.